Biphenyls as potent vitronectin receptor antagonists.: Part 3:: Squaric acid amides

被引：15
|
作者：
Urbahns, Klaus
Haerter, Michael
Albers, Markus
Schmidt, Delf
Stelte-Ludwig, Beatrix
Brueggemeier, Ulf
Vaupel, Andrea
Keldenich, Joerg
Lustig, Klemens
Tsujishita, Hideki
Gerdes, Christoph
机构：
[1] Bayer Schering Pharma, Bayer Hlthcare AG, Inst Med Chem, D-42096 Wuppertal, Germany
[2] Bayer AG, Combinat Chem Grp, D-51368 Leverkusen, Germany
[3] Bayer Schering Pharma, Bayer Hlthcare AG, Inst Lead Discovery, D-42096 Wuppertal, Germany
[4] Bayer Schering Pharma, Bayer Hlthcare AG, Inst Prot Therapeut, D-42096 Wuppertal, Germany
[5] Bayer Schering Pharma, Bayer Hlthcare AG, Inst Drug Metab & Pharmacol, D-42096 Wuppertal, Germany
[6] Bayer Yakutin Res Ctr, Dept Med Chem, Kyoto, Japan
[7] Bayer Schering Pharma, Bayer Hlthcare AG, Inst Cardiol Hematol, D-42096 Wuppertal, Germany
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 22期
关键词：
vitronectin; urea; arginine; guanidine mimetic; squaric acid amide; alpha nu beta(3); RGD; restenosis; biphenyl; smooth muscle cell;
D O I：
10.1016/j.bmcl.2007.09.039
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Vitronectin receptor (alpha(V)beta 3) antagonists have been implicated as a possible new treatment of restenosis following balloon angioplasty. In this work we investigate a series of novel arginine mimetic scaffolds leading to new insight of the alpha(V)beta 3/ligand interaction. Squaric acid amide 10 is a subnanomolar alpha(V)beta 3 antagonist with improved potency on human smooth muscle cell migration. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6151 / 6154
页数：4
相关论文
共 50 条
  • [21] Discovery of potent, non-peptide thrombin receptor antagonists.
    Chackalamannil, S
    Xia, Y
    Clasby, M
    Greenlee, W
    Doller, D
    Eagen, K
    Tsai, HS
    Asberom, T
    Lin, Y
    Czarniecki, M
    Ahn, HS
    Foster, C
    Boykow, G
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U60 - U60
  • [22] Molecular modeling of lysophosphatidic acid receptor antagonists.
    Sardar, VM
    Virag, T
    Fischer, DJ
    Elrod, D
    Bautista, DL
    Wang, DA
    Nusser, N
    Yokoyama, K
    Baker, DL
    Miller, DD
    Tigyi, G
    Parrill, AL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U19 - U19
  • [23] Design of potent non-imidazole histamine H3-receptor antagonists.
    Ganellin, CR
    Leurquin, F
    Akinleminu, TT
    Halai, S
    Zhao, YH
    Stark, H
    Schunack, W
    Ligneau, X
    Arrang, JM
    Schwartz, JC
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U9 - U9
  • [24] Potent, selective, orally active, nonpeptide vasopressin receptor antagonists.
    Matthews, JM
    Dyatkin, AB
    Hecker, L
    Hlasta, DJ
    Hoekstra, WJ
    Poulter, B
    Andrade-Gordon, P
    de Garavilla, L
    Demarest, K
    Ericson, E
    Gunnet, J
    Hagman, W
    Look, R
    Moore, J
    Reynolds, CH
    Maryanoff, BE
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U913 - U914
  • [25] Acyl-D-alanine amides:: Selective histamine H3 receptor antagonists.
    Black, LA
    Faghih, R
    Liu, HQ
    Dwight, W
    Phelan, KM
    Gentles, RG
    Esbenshade, TA
    Ireland, LM
    Miller, TR
    Kang, CH
    Parihar, AS
    Krueger, KM
    Fox, GB
    Bennani, YL
    Hancock, AA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U63 - U63
  • [26] Synthesis of potent, nonpeptide integrin αvβ3 antagonists.
    Ishikawa, M
    Yamamoto, M
    Kubota, D
    Yahata, N
    Kuroda, C
    Yasuda, S
    Fujishima, K
    Hachisu, M
    Katano, K
    Murakami, S
    Ajito, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U931 - U932
  • [27] Nonpeptide αvβ3 antagonists.: Part 11:: Discovery and preclinical evaluation of potent αvβ3 antagonists for the prevention and treatment of osteoporosis
    Coleman, PJ
    Brashear, KM
    Askew, BC
    Hutchinson, JH
    McVean, CA
    Duong, LT
    Feuston, BP
    Fernandez-Metzler, C
    Gentile, MA
    Hartman, GD
    Kimmel, DB
    Leu, CT
    Lipfert, L
    Merkle, K
    Pennypacker, B
    Prueksaritanont, T
    Rodan, GA
    Wesolowski, GA
    Rodan, SB
    Duggan, ME
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (20) : 4829 - 4837
  • [28] Synthesis and in-vitro potency of novel quinazolinone-based vitronectin receptor antagonists.
    Lawson, EC
    Costanzo, MJ
    Hoekstra, WJ
    Kinney, WA
    Luci, DK
    Maryanoff, BE
    Wisnoski, D
    Yabut, SC
    Andrade-Gordon, P
    Kauffman, JA
    Santulli, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U652 - U653
  • [29] Novel amides as potent and selective histamine H3 receptor antagonists
    Nirogi, Ramakrishna
    Shinde, Anil
    Kambhampati, Ramasastri
    Deshpande, Amol
    Dwarampudi, Adireddy
    Gangadasari, Narsimhareddy
    Cheppala, Atreya
    Rambabu, Namala
    Kandikere, Vishwottam
    Jayarajan, Pradeep
    Muddana, Nageswararao
    Ahmad, Ishtiyaque
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [30] Nonpeptide αvβ3 antagonists.: Part 2:: Constrained glycyl amides derived from the RGD tripeptide
    Meissner, RS
    Perkins, JJ
    Duong, LT
    Hartman, GD
    Hoffman, WF
    Huff, JR
    Ihle, NC
    Leu, CT
    Nagy, RM
    Naylor-Olsen, A
    Rodan, GA
    Rodan, SB
    Whitman, DB
    Wesolowski, GA
    Duggan, ME
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (01) : 25 - 29
12345